Oldest pages

Jump to navigation Jump to search

Showing below up to 500 results in range #251 to #750.

View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)

  1. Connective tissue‏‎ (19:21, 12 September 2019)
  2. Consequential late effects‏‎ (19:21, 12 September 2019)
  3. Constancy test‏‎ (19:21, 12 September 2019)
  4. Contamination‏‎ (19:22, 12 September 2019)
  5. Coronary heart disease‏‎ (19:23, 12 September 2019)
  6. Cost-benefit analysis‏‎ (19:24, 12 September 2019)
  7. Coster-Kronig transition‏‎ (19:25, 12 September 2019)
  8. Curie‏‎ (19:25, 12 September 2019)
  9. Cytokines‏‎ (19:26, 12 September 2019)
  10. Decay constant‏‎ (19:28, 12 September 2019)
  11. Decommissioning‏‎ (19:28, 12 September 2019)
  12. Decontamination‏‎ (19:29, 12 September 2019)
  13. Decontamination factor‏‎ (19:29, 12 September 2019)
  14. Deontological Ethics‏‎ (19:30, 12 September 2019)
  15. Diastasis‏‎ (19:30, 12 September 2019)
  16. Dichotomous‏‎ (19:31, 12 September 2019)
  17. Differentiation‏‎ (19:31, 12 September 2019)
  18. In vivo radiobioassay‏‎ (19:32, 12 September 2019)
  19. Disposal‏‎ (19:33, 12 September 2019)
  20. DNA damage signalling‏‎ (19:33, 12 September 2019)
  21. Dose constraint‏‎ (19:35, 12 September 2019)
  22. Dose criteria‏‎ (19:35, 12 September 2019)
  23. Dose limit‏‎ (19:36, 12 September 2019)
  24. Dose per unit intake coefficient‏‎ (19:37, 12 September 2019)
  25. Dose rate‏‎ (19:38, 12 September 2019)
  26. Dose rate effectiveness factor‏‎ (19:38, 12 September 2019)
  27. Dose-rate effect‏‎ (19:39, 12 September 2019)
  28. Dose-threshold‏‎ (19:40, 12 September 2019)
  29. Early normal tissue responses‏‎ (19:43, 12 September 2019)
  30. Edema‏‎ (19:44, 12 September 2019)
  31. Effect Dose 50‏‎ (19:45, 12 September 2019)
  32. Effective charge number‏‎ (19:46, 12 September 2019)
  33. Effective dose equivalent‏‎ (19:47, 12 September 2019)
  34. Effective half-life‏‎ (19:49, 12 September 2019)
  35. Electron-capture decay‏‎ (19:49, 12 September 2019)
  36. Electrophysiology‏‎ (19:51, 12 September 2019)
  37. Emergency‏‎ (19:52, 12 September 2019)
  38. Emergency exposure situation‏‎ (19:52, 12 September 2019)
  39. Emergency plan‏‎ (19:53, 12 September 2019)
  40. Emergency preparedness‏‎ (19:53, 12 September 2019)
  41. Emergency procedures‏‎ (19:53, 12 September 2019)
  42. Endogeneous excretion‏‎ (19:54, 12 September 2019)
  43. Environmental exposure‏‎ (19:55, 12 September 2019)
  44. Environmental radiation protection‏‎ (19:55, 12 September 2019)
  45. Epithelium‏‎ (19:56, 12 September 2019)
  46. Erythropoietin‏‎ (19:57, 12 September 2019)
  47. Ethics‏‎ (19:58, 12 September 2019)
  48. Exempt waste‏‎ (19:59, 12 September 2019)
  49. Exemption level‏‎ (19:59, 12 September 2019)
  50. Existing exposure situation‏‎ (20:00, 12 September 2019)
  51. Exponential survival curve‏‎ (20:01, 12 September 2019)
  52. Exposure, external or internal‏‎ (20:01, 12 September 2019)
  53. Exposure situation‏‎ (20:02, 12 September 2019)
  54. Habitual mouth breather‏‎ (12:42, 13 September 2019)
  55. Habitual nose breather‏‎ (12:42, 13 September 2019)
  56. Half-life, physical‏‎ (12:43, 13 September 2019)
  57. Hazard‏‎ (12:43, 13 September 2019)
  58. Health Surveillance‏‎ (12:43, 13 September 2019)
  59. Heliosphere‏‎ (12:44, 13 September 2019)
  60. Hierarchical tissues‏‎ (12:44, 13 September 2019)
  61. High level waste‏‎ (12:45, 13 September 2019)
  62. Hormones‏‎ (12:45, 13 September 2019)
  63. Hyperbaric oxygen‏‎ (12:46, 13 September 2019)
  64. Hypertrophic cardiomyopathy‏‎ (12:48, 13 September 2019)
  65. Hypoplasia‏‎ (12:48, 13 September 2019)
  66. Immune system‏‎ (12:49, 13 September 2019)
  67. Incident‏‎ (12:50, 13 September 2019)
  68. Inclusiveness‏‎ (12:50, 13 September 2019)
  69. Individual decontamination‏‎ (12:50, 13 September 2019)
  70. Individual monitoring‏‎ (12:51, 13 September 2019)
  71. Individual-related‏‎ (12:51, 13 September 2019)
  72. Inhalability‏‎ (12:53, 13 September 2019)
  73. Inner bremsstrahlung‏‎ (12:53, 13 September 2019)
  74. Institutional control‏‎ (12:54, 13 September 2019)
  75. Intermediate level waste‏‎ (12:54, 13 September 2019)
  76. Internal conversion electron‏‎ (12:56, 13 September 2019)
  77. Interphase death‏‎ (12:56, 13 September 2019)
  78. Intervention Level‏‎ (12:56, 13 September 2019)
  79. Interventional procedure‏‎ (12:57, 13 September 2019)
  80. Iso-effect plots‏‎ (12:58, 13 September 2019)
  81. Isomers‏‎ (12:58, 13 September 2019)
  82. Isotropic geometry‏‎ (12:58, 13 September 2019)
  83. Itinerant (radiation) worker‏‎ (12:59, 13 September 2019)
  84. Latent time/period or latency interval‏‎ (13:01, 13 September 2019)
  85. Limitation of dose‏‎ (13:01, 13 September 2019)
  86. Lineal energy‏‎ (13:02, 13 September 2019)
  87. Linear-non-threshold model‏‎ (13:03, 13 September 2019)
  88. Low level waste‏‎ (13:08, 13 September 2019)
  89. Lymphatic system‏‎ (13:08, 13 September 2019)
  90. Macrophage colony stimulating factor‏‎ (13:08, 13 September 2019)
  91. Magnetosphere‏‎ (13:09, 13 September 2019)
  92. Member of the public‏‎ (13:10, 13 September 2019)
  93. Mendelian diseases‏‎ (13:10, 13 September 2019)
  94. Mitigation‏‎ (13:10, 13 September 2019)
  95. Multistage tumorigenesis‏‎ (13:11, 13 September 2019)
  96. Myocardial perfusion‏‎ (13:12, 13 September 2019)
  97. Myocardial stress test‏‎ (13:13, 13 September 2019)
  98. Naturally occurring radioactive material‏‎ (13:14, 13 September 2019)
  99. Necrosis‏‎ (13:14, 13 September 2019)
  100. Neurological syndrome‏‎ (13:14, 13 September 2019)
  101. Neurovascular syndrome‏‎ (13:15, 13 September 2019)
  102. Non-sphericity parameter‏‎ (13:16, 13 September 2019)
  103. Nuclear track detectors‏‎ (13:17, 13 September 2019)
  104. Particle radiance‏‎ (13:28, 13 September 2019)
  105. Peak skin dose‏‎ (13:28, 13 September 2019)
  106. Pelagic‏‎ (13:29, 13 September 2019)
  107. Percutaneous coronary intervention‏‎ (13:29, 13 September 2019)
  108. Pericarditis‏‎ (13:29, 13 September 2019)
  109. Pharynx‏‎ (13:30, 13 September 2019)
  110. Planned exposure situation‏‎ (13:30, 13 September 2019)
  111. Platelet-derived growth factor‏‎ (13:30, 13 September 2019)
  112. Practical radiological protection culture‏‎ (13:32, 13 September 2019)
  113. Prevailing circumstances‏‎ (13:32, 13 September 2019)
  114. Principle of application of dose limits‏‎ (13:32, 13 September 2019)
  115. Principle of justification‏‎ (13:33, 13 September 2019)
  116. Principle of optimisation‏‎ (13:33, 13 September 2019)
  117. Procedural values‏‎ (13:34, 13 September 2019)
  118. Progenitor cell‏‎ (13:35, 13 September 2019)
  119. Projected dose‏‎ (13:36, 13 September 2019)
  120. Protection strategy‏‎ (13:37, 13 September 2019)
  121. Protective action‏‎ (13:37, 13 September 2019)
  122. Protective action guide‏‎ (13:38, 13 September 2019)
  123. Public exposure‏‎ (13:39, 13 September 2019)
  124. Radiation modifier‏‎ (13:41, 13 September 2019)
  125. Radiation safety officer‏‎ (13:42, 13 September 2019)
  126. Radiation worker‏‎ (13:44, 13 September 2019)
  127. Radioactive dispersion device‏‎ (13:44, 13 September 2019)
  128. Radioactive source‏‎ (13:45, 13 September 2019)
  129. Radioactive substance‏‎ (13:46, 13 September 2019)
  130. Radioactivity‏‎ (13:46, 13 September 2019)
  131. Radiofrequency ablation‏‎ (13:46, 13 September 2019)
  132. Radiographer‏‎ (13:48, 13 September 2019)
  133. Radiological protection principles‏‎ (13:49, 13 September 2019)
  134. Radionuclides of natural origin‏‎ (13:49, 13 September 2019)
  135. Radioresponsiveness‏‎ (13:49, 13 September 2019)
  136. Radiosensitiser‏‎ (13:50, 13 September 2019)
  137. Radiosensitivity, cellular‏‎ (13:50, 13 September 2019)
  138. Reasonableness‏‎ (13:50, 13 September 2019)
  139. Recovery‏‎ (13:51, 13 September 2019)
  140. Recovery responder‏‎ (13:51, 13 September 2019)
  141. Reference bioassay function‏‎ (13:51, 13 September 2019)
  142. Reference biokinetic model‏‎ (13:52, 13 September 2019)
  143. Reference level‏‎ (13:52, 13 September 2019)
  144. Rehabilitation of living conditions‏‎ (13:52, 13 September 2019)
  145. Relocation‏‎ (13:53, 13 September 2019)
  146. Remedial action‏‎ (13:53, 13 September 2019)
  147. Remediation‏‎ (13:53, 13 September 2019)
  148. Repopulation‏‎ (13:54, 13 September 2019)
  149. Representative organism (non-human biota)‏‎ (13:54, 13 September 2019)
  150. Representative person‏‎ (13:54, 13 September 2019)
  151. Reproductive integrity‏‎ (13:55, 13 September 2019)
  152. Residual dose‏‎ (13:55, 13 September 2019)
  153. Respiratory protection‏‎ (13:55, 13 September 2019)
  154. Retrievability‏‎ (13:56, 13 September 2019)
  155. Reversibility‏‎ (13:56, 13 September 2019)
  156. Right to know‏‎ (13:57, 13 September 2019)
  157. Rigidity‏‎ (13:58, 13 September 2019)
  158. Routine monitoring‏‎ (13:58, 13 September 2019)
  159. Safety case‏‎ (13:59, 13 September 2019)
  160. Safety culture‏‎ (13:59, 13 September 2019)
  161. Scintigraphy‏‎ (13:59, 13 September 2019)
  162. Self-help protection‏‎ (14:00, 13 September 2019)
  163. Slow repair‏‎ (14:01, 13 September 2019)
  164. Solar cosmic radiation‏‎ (14:01, 13 September 2019)
  165. Solar cycle‏‎ (14:01, 13 September 2019)
  166. Solar particle event‏‎ (14:01, 13 September 2019)
  167. Source term‏‎ (14:02, 13 September 2019)
  168. Source-related‏‎ (14:02, 13 September 2019)
  169. South Atlantic anomaly‏‎ (14:03, 13 September 2019)
  170. Special (non-routine) monitoring‏‎ (14:03, 13 September 2019)
  171. Spontaneous fission‏‎ (14:03, 13 September 2019)
  172. Stakeholder‏‎ (14:04, 13 September 2019)
  173. Stenosis‏‎ (14:04, 13 September 2019)
  174. Storage‏‎ (14:04, 13 September 2019)
  175. Subcutaneous tissue‏‎ (14:05, 13 September 2019)
  176. Substantial radiation dose level‏‎ (14:05, 13 September 2019)
  177. Systemic model‏‎ (14:06, 13 September 2019)
  178. Tachycardia‏‎ (14:10, 13 September 2019)
  179. Target region‏‎ (14:10, 13 September 2019)
  180. Target tissue‏‎ (14:10, 13 September 2019)
  181. Telangiectasia‏‎ (14:11, 13 September 2019)
  182. Threshold dose for tissue reactions‏‎ (14:11, 13 September 2019)
  183. Thyroid blocking‏‎ (14:11, 13 September 2019)
  184. Time factor‏‎ (14:11, 13 September 2019)
  185. Tissue equivalent material‏‎ (14:12, 13 September 2019)
  186. Tolerability‏‎ (14:12, 13 September 2019)
  187. Track structure‏‎ (14:13, 13 September 2019)
  188. Transfer compartment‏‎ (14:14, 13 September 2019)
  189. Transfer rate‏‎ (14:14, 13 September 2019)
  190. Transforming growth factor‏‎ (14:15, 13 September 2019)
  191. Transparency‏‎ (14:15, 13 September 2019)
  192. Trapped particles‏‎ (14:16, 13 September 2019)
  193. Types of materials‏‎ (14:16, 13 September 2019)
  194. Application of ionising radiation in healthcare (old)‏‎ (18:00, 9 October 2019)
  195. Information for patients, family members, carers and the public (old)‏‎ (18:00, 9 October 2019)
  196. Information for healthcare providers (old)‏‎ (18:00, 9 October 2019)
  197. Application of ionising radiation in healthcare‏‎ (18:04, 9 October 2019)
  198. Information for patients, family members, carers and the public‏‎ (18:11, 9 October 2019)
  199. Information for healthcare providers‏‎ (18:21, 9 October 2019)
  200. ICRPædia Guides‏‎ (18:33, 9 October 2019)
  201. List of ICRP Publications on Radiological Protection in Healthcare‏‎ (13:57, 17 October 2019)
  202. Guide to Radiological Protection in Healthcare‏‎ (13:59, 17 October 2019)
  203. The System of Radiological Protection‏‎ (15:15, 23 October 2019)
  204. Quotes from Publications on the System of Radiological Protection‏‎ (17:58, 23 October 2019)
  205. Guide to the System of Radiological Protection‏‎ (15:40, 24 October 2019)
  206. General Information on Radon‏‎ (12:41, 30 October 2019)
  207. System Of Radiation Protection Overview‏‎ (15:02, 4 November 2019)
  208. System of radiation protection module 2‏‎ (15:11, 4 November 2019)
  209. Absorbed, Equivalent, and Effective Dose‏‎ (21:54, 21 November 2019)
  210. Radon For Governments and Employers‏‎ (18:19, 3 December 2019)
  211. Radon For Homeowners and Residents‏‎ (18:19, 3 December 2019)
  212. Guide to Radon‏‎ (07:37, 5 February 2020)
  213. Main Page‏‎ (12:31, 18 November 2020)
  214. Additive risk projection model‏‎ (20:28, 24 February 2021)
  215. Attributable risk‏‎ (20:30, 24 February 2021)
  216. Dicentric chromosome‏‎ (20:31, 24 February 2021)
  217. Effect modifier‏‎ (20:32, 24 February 2021)
  218. Hereditary effect‏‎ (20:33, 24 February 2021)
  219. Low dose‏‎ (20:33, 24 February 2021)
  220. Low dose rate‏‎ (20:35, 24 February 2021)
  221. Multiplicative risk projection model‏‎ (20:36, 24 February 2021)
  222. Ring chromosome‏‎ (20:38, 24 February 2021)
  223. Severe deterministic injury‏‎ (20:38, 24 February 2021)
  224. Somatic effect‏‎ (20:39, 24 February 2021)
  225. Transgenerational effect‏‎ (20:40, 24 February 2021)
  226. Detriment-adjusted risk‏‎ (20:42, 24 February 2021)
  227. Elemental dose‏‎ (20:44, 24 February 2021)
  228. Multistage carcinogenesis model‏‎ (20:50, 24 February 2021)
  229. Mutation component‏‎ (20:51, 24 February 2021)
  230. Oncogene‏‎ (20:52, 24 February 2021)
  231. Population risk‏‎ (20:53, 24 February 2021)
  232. Potentially lethal damage repair‏‎ (20:54, 24 February 2021)
  233. Radiation risk‏‎ (20:55, 24 February 2021)
  234. Relative life lost‏‎ (20:56, 24 February 2021)
  235. Risk model‏‎ (20:57, 24 February 2021)
  236. Sublethal damage repair‏‎ (20:58, 24 February 2021)
  237. Transfer of risk‏‎ (20:59, 24 February 2021)
  238. Tumour suppressor gene‏‎ (21:00, 24 February 2021)
  239. Acute radiation syndrome‏‎ (21:40, 24 February 2021)
  240. Adaptive response‏‎ (21:42, 24 February 2021)
  241. Α/β value‏‎ (21:46, 24 February 2021)
  242. ΓH2AX foci‏‎ (21:46, 24 February 2021)
  243. Informed consent‏‎ (21:49, 24 February 2021)
  244. Supervised area‏‎ (21:51, 24 February 2021)
  245. Access control‏‎ (21:52, 24 February 2021)
  246. Acute exposure‏‎ (21:54, 24 February 2021)
  247. Adventitious source‏‎ (21:55, 24 February 2021)
  248. Authorised discharge‏‎ (21:57, 24 February 2021)
  249. Backscatter factor‏‎ (21:59, 24 February 2021)
  250. Best available techniques‏‎ (22:00, 24 February 2021)
  251. Disposal facility‏‎ (22:02, 24 February 2021)
  252. Dose modifying factor‏‎ (22:03, 24 February 2021)
  253. Exposure pathway‏‎ (22:05, 24 February 2021)
  254. Radiological controlled area‏‎ (22:07, 24 February 2021)
  255. Life Span Study‏‎ (22:10, 24 February 2021)
  256. Detriment‏‎ (19:17, 25 February 2021)
  257. Baseline disease rates‏‎ (19:29, 25 February 2021)
  258. Biomarker‏‎ (19:31, 25 February 2021)
  259. Case–control study‏‎ (19:33, 25 February 2021)
  260. Deterministic effect‏‎ (19:38, 25 February 2021)
  261. Dose and dose-rate effectiveness factor‏‎ (15:54, 26 February 2021)
  262. Dose-threshold hypothesis‏‎ (15:56, 26 February 2021)
  263. Tissue reaction‏‎ (16:00, 26 February 2021)
  264. Doubling dose‏‎ (17:10, 26 February 2021)
  265. Epigenetic effects‏‎ (17:13, 26 February 2021)
  266. Excess absolute risk‏‎ (17:16, 26 February 2021)
  267. Excess relative risk‏‎ (17:25, 26 February 2021)
  268. Homologous recombination‏‎ (17:26, 26 February 2021)
  269. Incidence‏‎ (17:28, 26 February 2021)
  270. Induced genomic instability‏‎ (17:30, 26 February 2021)
  271. Late normal tissue responses‏‎ (17:31, 26 February 2021)
  272. LD 50/30‏‎ (17:33, 26 February 2021)
  273. Lifetime risk estimates‏‎ (17:42, 26 February 2021)
  274. Linear dose response‏‎ (17:43, 26 February 2021)
  275. Linear-quadratic dose response model‏‎ (17:48, 26 February 2021)
  276. Stochastic effect‏‎ (17:58, 26 February 2021)
  277. Nominal risk coefficient‏‎ (19:29, 26 February 2021)
  278. Non-homologous end joining‏‎ (19:30, 26 February 2021)
  279. Non-targeted effects‏‎ (19:31, 26 February 2021)
  280. Normal tissue complication probability‏‎ (19:33, 26 February 2021)
  281. Pooled analysis‏‎ (19:34, 26 February 2021)
  282. Quasi-threshold dose‏‎ (19:35, 26 February 2021)
  283. Reactive oxygen species‏‎ (19:36, 26 February 2021)
  284. Recovery (cellular or tissue)‏‎ (19:38, 26 February 2021)
  285. Reference Animal and Plant‏‎ (19:43, 26 February 2021)
  286. Relative biological effectiveness‏‎ (20:22, 26 February 2021)
  287. Relative risk‏‎ (20:25, 26 February 2021)
  288. Risk coefficient‏‎ (20:30, 26 February 2021)
  289. Targeted effects‏‎ (20:32, 26 February 2021)
  290. Translocation‏‎ (20:33, 26 February 2021)
  291. Radiation source‏‎ (21:04, 26 February 2021)
  292. Dose-response function‏‎ (14:57, 28 March 2021)
  293. Tissue weighting factor‏‎ (21:32, 28 March 2021)
  294. Absorption‏‎ (22:15, 28 March 2021)
  295. Activation‏‎ (22:16, 28 March 2021)
  296. Activity‏‎ (22:19, 28 March 2021)
  297. ICRPædia Guide to the System of Radiological Protection‏‎ (21:44, 3 May 2021)
  298. Active detection system‏‎ (19:35, 11 August 2021)
  299. Additional dose‏‎ (19:36, 11 August 2021)
  300. Allometry‏‎ (19:37, 11 August 2021)
  301. Commissioning‏‎ (19:42, 11 August 2021)
  302. Compartment (environmental)‏‎ (19:44, 11 August 2021)
  303. Accreditation‏‎ (19:45, 11 August 2021)
  304. Backscatter detection system‏‎ (19:48, 11 August 2021)
  305. Clearance‏‎ (19:50, 11 August 2021)
  306. Concentration ratio‏‎ (19:52, 11 August 2021)
  307. Containment‏‎ (19:56, 11 August 2021)
  308. Cosmic radiation‏‎ (19:57, 11 August 2021)
  309. Derived reference level‏‎ (20:00, 11 August 2021)
  310. Derived limit‏‎ (20:00, 11 August 2021)
  311. Derived consideration reference level‏‎ (20:02, 11 August 2021)
  312. Designated area‏‎ (20:03, 11 August 2021)
  313. Evacuation‏‎ (20:07, 11 August 2021)
  314. Exclusion‏‎ (20:08, 11 August 2021)
  315. Exposed individuals‏‎ (20:09, 11 August 2021)
  316. Frequent flyer‏‎ (20:11, 11 August 2021)
  317. Ground-level enhancement‏‎ (20:12, 11 August 2021)
  318. ICRU 4-element tissue‏‎ (20:14, 11 August 2021)
  319. ICRU sphere‏‎ (20:17, 11 August 2021)
  320. Intervention‏‎ (20:18, 11 August 2021)
  321. Licensee‏‎ (20:20, 11 August 2021)
  322. National radon survey‏‎ (20:20, 11 August 2021)
  323. Nominal value‏‎ (20:21, 11 August 2021)
  324. Occupancy factor‏‎ (20:22, 11 August 2021)
  325. Operating management‏‎ (20:23, 11 August 2021)
  326. Potential exposure‏‎ (23:17, 11 August 2021)
  327. Collective dose‏‎ (23:18, 11 August 2021)
  328. Optimisation of protection‏‎ (23:22, 11 August 2021)
  329. Practice‏‎ (23:25, 11 August 2021)
  330. Principles of protection‏‎ (23:25, 11 August 2021)
  331. Radioactive waste‏‎ (23:29, 11 August 2021)
  332. Radiological attack‏‎ (23:30, 11 August 2021)
  333. Radon progeny‏‎ (23:30, 11 August 2021)
  334. Radon-prone area‏‎ (23:31, 11 August 2021)
  335. Redox‏‎ (23:31, 11 August 2021)
  336. Reference value‏‎ (23:34, 11 August 2021)
  337. Safety‏‎ (23:36, 11 August 2021)
  338. Region‏‎ (23:36, 11 August 2021)
  339. Sealed source‏‎ (23:38, 11 August 2021)
  340. Solar flare‏‎ (23:59, 11 August 2021)
  341. Sheltering‏‎ (00:00, 12 August 2021)
  342. Security‏‎ (00:01, 12 August 2021)
  343. Security screening‏‎ (00:02, 12 August 2021)
  344. Protection quantities‏‎ (14:51, 12 August 2021)
  345. Source-related assessment‏‎ (14:53, 12 August 2021)
  346. Superposition principle‏‎ (14:55, 12 August 2021)
  347. Surface contamination‏‎ (14:56, 12 August 2021)
  348. Thoron progeny‏‎ (14:57, 12 August 2021)
  349. Transmission detection system‏‎ (14:59, 12 August 2021)
  350. Trophic level‏‎ (15:00, 12 August 2021)
  351. Waste management‏‎ (15:05, 12 August 2021)
  352. Worker‏‎ (15:08, 12 August 2021)
  353. Working level‏‎ (15:14, 12 August 2021)
  354. Working level month‏‎ (15:17, 12 August 2021)
  355. Adenoma‏‎ (15:24, 12 August 2021)
  356. Air kerma at the patient entrance reference point‏‎ (15:27, 12 August 2021)
  357. Apoptosis‏‎ (15:29, 12 August 2021)
  358. AML/eto‏‎ (15:30, 12 August 2021)
  359. Automatic exposure control‏‎ (15:33, 12 August 2021)
  360. Brachytherapy‏‎ (15:34, 12 August 2021)
  361. Bragg peak‏‎ (15:37, 12 August 2021)
  362. Spread-out Bragg peak‏‎ (15:39, 12 August 2021)
  363. Breakpoint cluster region/abelson‏‎ (15:41, 12 August 2021)
  364. Broad beam therapy irradiation technique‏‎ (15:44, 12 August 2021)
  365. Carers and comforters‏‎ (15:48, 12 August 2021)
  366. Clinical audit‏‎ (15:50, 12 August 2021)
  367. Clonogenic surviving fraction‏‎ (15:52, 12 August 2021)
  368. Cobblestone area forming cell assay‏‎ (15:53, 12 August 2021)
  369. Collimation‏‎ (15:54, 12 August 2021)
  370. Cone beam computed tomography‏‎ (15:56, 12 August 2021)
  371. Dental and maxillofacial imaging‏‎ (16:01, 12 August 2021)
  372. Exposure index‏‎ (16:03, 12 August 2021)
  373. Detector quantum efficiency‏‎ (16:04, 12 August 2021)
  374. Diagnostic reference level‏‎ (16:09, 12 August 2021)
  375. Dose-length product‏‎ (16:11, 12 August 2021)
  376. DRL process‏‎ (16:14, 12 August 2021)
  377. DRL quantity‏‎ (16:18, 12 August 2021)
  378. Exogenous excretion‏‎ (16:19, 12 August 2021)
  379. Functional subunits‏‎ (16:24, 12 August 2021)
  380. Hounsfield unit‏‎ (16:43, 12 August 2021)
  381. Accelerated fractionation‏‎ (16:45, 12 August 2021)
  382. Hyperfractionation‏‎ (16:45, 12 August 2021)
  383. Intensity-modulated radiotherapy‏‎ (16:46, 12 August 2021)
  384. Local DRL‏‎ (16:49, 12 August 2021)
  385. National DRL‏‎ (16:50, 12 August 2021)
  386. DRL value‏‎ (16:51, 12 August 2021)
  387. Mean glandular dose‏‎ (17:28, 12 August 2021)
  388. Multi-detector computed tomography‏‎ (17:31, 12 August 2021)
  389. Multifactorial diseases‏‎ (17:31, 12 August 2021)
  390. Multitarget equation‏‎ (17:37, 12 August 2021)
  391. Noise‏‎ (17:38, 12 August 2021)
  392. Notification value‏‎ (17:41, 12 August 2021)
  393. Nuclear medicine‏‎ (17:42, 12 August 2021)
  394. Molecular imaging‏‎ (17:43, 12 August 2021)
  395. Organ at risk‏‎ (17:44, 12 August 2021)
  396. Oxygen enhancement ratio‏‎ (17:45, 12 August 2021)
  397. Pencil beam‏‎ (17:46, 12 August 2021)
  398. Pilomatricoma‏‎ (17:47, 12 August 2021)
  399. Potential recoverability correction factor‏‎ (17:49, 12 August 2021)
  400. Quality control testing‏‎ (17:51, 12 August 2021)
  401. Radiation-induced second cancer‏‎ (17:52, 12 August 2021)
  402. Radiation-induced secondary malignancy‏‎ (17:53, 12 August 2021)
  403. Ras‏‎ (17:55, 12 August 2021)
  404. Rb‏‎ (17:56, 12 August 2021)
  405. Referrer‏‎ (17:57, 12 August 2021)
  406. Reference air kerma‏‎ (17:59, 12 August 2021)
  407. Regional diagnostic reference levels‏‎ (18:01, 12 August 2021)
  408. Registry‏‎ (18:02, 12 August 2021)
  409. Relative survival‏‎ (18:03, 12 August 2021)
  410. Secondary radiation‏‎ (18:04, 12 August 2021)
  411. Shielding‏‎ (18:05, 12 August 2021)
  412. Size-specific dose estimate‏‎ (18:06, 12 August 2021)
  413. Slice‏‎ (18:07, 12 August 2021)
  414. Standard-size adult‏‎ (18:09, 12 August 2021)
  415. Stem cell‏‎ (18:10, 12 August 2021)
  416. Teratocarcinoma‏‎ (18:11, 12 August 2021)
  417. Time-resolved computed tomography‏‎ (18:13, 12 August 2021)
  418. Tolerance dose‏‎ (18:14, 12 August 2021)
  419. Digital breast tomosynthesis‏‎ (18:15, 12 August 2021)
  420. Treatment preparation in radiotherapy‏‎ (18:16, 12 August 2021)
  421. Typical value‏‎ (18:18, 12 August 2021)
  422. Absorbed fraction‏‎ (18:24, 12 August 2021)
  423. Source region‏‎ (18:27, 12 August 2021)
  424. Activity median aerodynamic diameter‏‎ (18:29, 12 August 2021)
  425. Ambient dose equivalent‏‎ (18:30, 12 August 2021)
  426. Annual intake‏‎ (18:31, 12 August 2021)
  427. Annual limit on intake‏‎ (18:37, 12 August 2021)
  428. Derived air concentration‏‎ (18:41, 12 August 2021)
  429. Biological half-life‏‎ (18:43, 12 August 2021)
  430. Bronchiolar region‏‎ (18:44, 12 August 2021)
  431. Charged-particle equilibrium‏‎ (18:45, 12 August 2021)
  432. Collective effective dose‏‎ (19:04, 12 August 2021)
  433. Compartment‏‎ (19:06, 12 August 2021)
  434. Cross section‏‎ (19:10, 12 August 2021)
  435. Cumulative dose‏‎ (19:11, 12 August 2021)
  436. Deposition‏‎ (19:13, 12 August 2021)
  437. Derived investigation level‏‎ (19:14, 12 August 2021)
  438. Directional dose equivalent‏‎ (19:16, 12 August 2021)
  439. Distribution coefficient‏‎ (19:18, 12 August 2021)
  440. Dose‏‎ (19:22, 12 August 2021)
  441. Absorbed dose‏‎ (19:22, 12 August 2021)
  442. Equivalent dose‏‎ (19:32, 12 August 2021)
  443. Dose commitment‏‎ (19:40, 12 August 2021)
  444. Dose conversion convention‏‎ (19:46, 12 August 2021)
  445. Dose conversion factor‏‎ (19:47, 12 August 2021)
  446. Dose of record (E)‏‎ (19:50, 12 August 2021)
  447. Dose of record Hp (10)‏‎ (19:52, 12 August 2021)
  448. Dose per content function‏‎ (18:26, 17 August 2021)
  449. DS86‏‎ (18:29, 17 August 2021)
  450. DS02‏‎ (18:29, 17 August 2021)
  451. Endosteum‏‎ (18:34, 17 August 2021)
  452. Equieffective dose‏‎ (18:41, 17 August 2021)
  453. Equilibrium equivalent concentration‏‎ (18:43, 17 August 2021)
  454. Equilibrium factor‏‎ (02:06, 18 August 2021)
  455. Excretion rate (instantaneous)‏‎ (02:08, 18 August 2021)
  456. Expanded and aligned radiation field‏‎ (02:11, 18 August 2021)
  457. Expanded radiation field‏‎ (02:12, 18 August 2021)
  458. Exposure (in the context of inhalation)‏‎ (02:14, 18 August 2021)
  459. Extrathoracic airways‏‎ (02:18, 18 August 2021)
  460. Human Respiratory Tract Model‏‎ (02:31, 18 August 2021)
  461. Human Alimentary Tract Model‏‎ (02:33, 18 August 2021)
  462. Gray‏‎ (02:34, 18 August 2021)
  463. Intake‏‎ (02:39, 18 August 2021)
  464. Kerma approximation‏‎ (16:58, 18 August 2021)
  465. Low linear energy transfer radiation‏‎ (17:19, 18 August 2021)
  466. High linear energy transfer radiation‏‎ (17:21, 18 August 2021)
  467. Linear energy transfer‏‎ (17:23, 18 August 2021)
  468. Marrow cellularity‏‎ (17:25, 18 August 2021)
  469. Count median diameter‏‎ (17:38, 18 August 2021)
  470. Mass median diameter‏‎ (17:39, 18 August 2021)
  471. Activity median thermodynamic diameter‏‎ (17:41, 18 August 2021)
  472. Thermodynamic diameter‏‎ (17:42, 18 August 2021)
  473. Measured quantity‏‎ (17:45, 18 August 2021)
  474. Organ/tissue absorbed dose‏‎ (18:14, 18 August 2021)
  475. OLINDA/EXM‏‎ (18:17, 18 August 2021)
  476. Other (systemic) tissues‏‎ (18:23, 18 August 2021)
  477. Particle transport‏‎ (18:24, 18 August 2021)
  478. Dose equivalent‏‎ (18:34, 18 August 2021)
  479. Organ dose equivalent‏‎ (18:36, 18 August 2021)
  480. Personal dose equivalent‏‎ (18:42, 18 August 2021)
  481. Operational quantity‏‎ (18:45, 18 August 2021)
  482. Phantom‏‎ (18:46, 18 August 2021)
  483. Potential alpha energy concentration‏‎ (18:48, 18 August 2021)
  484. Quality factor‏‎ (19:14, 18 August 2021)
  485. Radiation weighting factor‏‎ (19:25, 18 August 2021)
  486. Sievert‏‎ (19:36, 18 August 2021)
  487. Specific effective energy‏‎ (19:40, 18 August 2021)
  488. Dose coefficient‏‎ (18:10, 19 August 2021)
  489. Dose conversion coefficient‏‎ (18:10, 19 August 2021)
  490. Effective dose‏‎ (18:28, 19 August 2021)
  491. Reference individual‏‎ (18:34, 19 August 2021)
  492. Reference parameter value‏‎ (18:35, 19 August 2021)
  493. Reference Person‏‎ (18:39, 19 August 2021)
  494. Reference phantom‏‎ (18:45, 19 August 2021)
  495. Reference worker‏‎ (18:46, 19 August 2021)
  496. S coefficient (radiation weighted)‏‎ (18:57, 19 August 2021)
  497. Specific absorbed fraction‏‎ (19:01, 19 August 2021)
  498. Spongiosa‏‎ (19:04, 19 August 2021)
  499. Thoracic airways‏‎ (19:10, 19 August 2021)
  500. Investigation level‏‎ (19:11, 19 August 2021)

View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)